An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design

CV Herst; S Burkholz; J Sidney; A Sette; PE Harris; S Massey; T Brasel; E Cunha-Neto; DS Rosa; WCH Chao; R Carback; T Hodge; L Wang; S Ciotlos; P Lloyd; R Rubsamen

The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.25.963546 doi: bioRxiv preprint antigens and the HLA restricted nature of CTL vaccines have limited their utility to protect individuals from infectious disease [77] . However, observations derived from individuals able to control HIV infection [43] and EBOV infection [50] demonstrating that control may be associated with specific CTL targeting behavior, suggest that there may be an important role for HLA-restricted peptide vaccines for protection against infectious disease for which development of The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.25.963546 doi: bioRxiv preprint matched Class II epitope using an adjuvanted microsphere peptide vaccine platform, NP44-52 protection against mortality and morbidity for the maEBOV challenge doses tested in a C57BL/6 mouse model. We accomplished this with an adjuvanted, microsphere-based, synthetic CTL peptide vaccine platform producing a protective immune response 14 days after a single administration.